EN
Therapeutic Areas
CytoSorbents Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CytoSorb® / CytoSorb 300® | Reduction of elevated cytokines, bilirubin, myoglobin | Commercial (CE Mark) |
| DrugSorb-ATR® | Removal of Ticagrelor/Rivaroxaban during cardio-pulmonary bypass surgery | Commercial (CE Mark) / Pivotal Trial (US) |
| ECOS-300CY® | Inflammatory mediator reduction during ex vivo organ perfusion | Investigational / Early Commercial |
| VetResQ® | Veterinary critical care (sepsis, pancreatitis, etc.) | Commercial |
| PuriFi® | Enabling device for independent CytoSorb® therapy | Commercial (CE Mark) |
Leadership Team at CytoSorbents
PP
Phillip P. Chan, MD, PhD
Chief Executive Officer
PJ
Peter J. Mariani
Chief Financial Officer
DW
Daniel Wendt, FECTS, FACS, MHBA
Vice President Medical Cardio-Vascular
HA
Harriet Adamson
Senior Manager Medical Information
DJ
Dr. Jörg Scheier
Vice President Medical Critical Care